Vinay Kammarchedu

Vinay Kammarchedu

Auto-generated profile, based on publicly available information

Vinay Kammarchedu

Department of Electrical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 May 2024 in Nanoscale
Verified
Journal Article
Open access
PDF file
VKVinay Kammarchedu
Vinay Kammarchedu
HAHeshmat Asgharian
Heshmat Asgharian
KZKeren Zhou
Keren Zhou
PKPouya Soltan Khamsi
Pouya Soltan Khamsi
Aida EbrahimiAida Ebrahimi
Aida Ebrahimi
Graphene, with its outstanding mechanical, electrical, and biocompatible properties, stands out as an emerging nanomaterial for healthcare applications, especially in building electroanalytical biodevices. With the rising prevalence of chronic diseases and infectious diseases, such as the COVID-19 pandemic, the demand for point-of-care testing and remote patient monitoring has never been greater. Owing to their portability, ease of manufacturing, scalability, and rapid and sensitive response, electroanalytical devices excel in these settings for improved healthcare accessibility, especially in resource-limited settings. The development of different synthesis methods yielding large-scale graphene and its derivatives with controllable properties, compatible with device manufacturing – from lithography to various printing methods – and tunable electrical, chemical, and electrochemical properties make it an attractive candidate for electroanalytical devices. This review article sheds light on how graphene-based devices can be transformative in addressing pressing healthcare needs, ranging from the fundamental understanding of biology in in vivo and ex vivo studies to early disease detection and management using in vitro assays and wearable devices. In particular, the article provides a special focus on (i) synthesis and functionalization techniques, emphasizing their suitability for scalable integration into devices, (ii) various transduction methods to design diverse electroanalytical device architectures, (iii) a myriad of applications using devices based on graphene, its derivatives, and hybrids with other nanomaterials, and (iv) emerging technologies at the intersection of device engineering and advanced data analytics. Finally, some of the major hurdles that graphene biodevices face for translation into clinical applications are discussed.

9 September 2025 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
HCHossein Chenani
Hossein Chenani
VKVinay Kammarchedu
Vinay Kammarchedu
HAHeshmat Asgharian
Heshmat Asgharian
Aida EbrahimiAida Ebrahimi
Aida Ebrahimi

4 September 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CBCaroline Ji-Mei Brustoloni
Caroline Ji-Mei Brustoloni
PKPouya Soltan Khamsi
Pouya Soltan Khamsi
VKVinay Kammarchedu
Vinay Kammarchedu
Aida EbrahimiAida Ebrahimi
Aida Ebrahimi

3 July 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
JBJulia M. Balsamo
Julia M. Balsamo
KZKeren Zhou
Keren Zhou
VKVinay Kammarchedu
Vinay Kammarchedu
Aida EbrahimiAida Ebrahimi
Aida Ebrahimi
EBElizabeth N. Bess
Elizabeth N. Bess
Aggregated deposits of the protein α-synuclein and depleting levels of dopamine in the brain correlate with Parkinson’s disease development. Treatments often focus on replenishing dopamine in the brain; however, the brain might not be the only site requiring attention. Aggregates of α-synuclein appear to accumulate in the gut years prior to the onset of any motor symptoms. Enteroendocrine cells (specialized gut epithelial cells) may be the source of intestinal α-synuclein, as they natively express this protein. Enteroendocrine cells are constantly exposed to gut bacteria and their metabolites because they border the gut lumen. These cells also express the dopamine metabolic pathway and form synapses with vagal neurons, which innervate the gut and brain. Through this connection, Parkinson’s disease pathology may originate in the gut and spread to the brain over time. Effective therapeutics to prevent this disease progression are lacking due to a limited understanding of the mechanisms by which α-synuclein aggregation occurs in the gut. We previously proposed a gut bacterial metabolic pathway responsible for the initiation of α-synuclein aggregation that is dependent on the oxidation of dopamine. Here, we develop a new tool, a laser-induced graphene-based electrochemical sensor chip, to track α-synuclein aggregation and dopamine level over time. Using these sensor chips, we evaluated diet-derived catechols dihydrocaffeic acid and caffeic acid as potential inhibitors of α-synuclein aggregation. Our results suggest that these molecules inhibit dopamine oxidation. We also found that these dietary catechols inhibit α-synuclein aggregation in STC-1 enteroendocrine cells. These findings are critical next steps to reveal new avenues for targeted therapeutics to treat Parkinson’s disease, specifically in the context of functional foods that may be used to reshape the gut environment.

22 February 2023 in IEEE Sensors Letters
Verified
Journal Article
Closed access
VKVinay Kammarchedu
Vinay Kammarchedu
Aida EbrahimiAida Ebrahimi
Aida Ebrahimi
High throughput and automated optical readout is already an industry standard in life sciences for screening several reactions at once. However, such high throughput systems are in an inceptive stage for electrochemical sensors. Such limitation, for example, slows down the process of establishing property-performance of novel materials for biochemical sensing. Herein, building on our prior work, we fabricate a low-cost customizable platform to screen response of acetic acid-treated laser induced graphene (AA-LIG) to identify and quantify four biogenic amine neurotransmitters in artificial saliva, namely dopamine (DA), serotonin (SER), epinephrine (EP), and norepinephrine (NEP), which due to similar molecular structures are difficult to differentiate using conventional electrochemical methods. Our screening platform analyzes multiple sensors at once and processes the data using machine learning to rapidly screen the material-molecule interactions by combining several electrochemical spectral components (fingerprints). Combining multiple spectral features, both within one electrochemical module and across different modules significantly improves the sensor performance and allows identification of the biomolecules using the same material system. The proposed automated electroanalytical system can be used to screen material-molecule interactions as well as high throughput point-of-care testing for rapid, multiplexed, and low-cost molecular detection.